Phase II Randomized-registry Embedded Study of Lymphoscintigraphy for Oropharyngeal Neoplasms to Enable Risk-adapted Nodal Guidance for Robotic Surgery and/or Radiotherapy (LONE-RANGR2)
PHASE2RecruitingINTERVENTIONAL
Enrollment
240
Participants
Timeline
Start Date
April 19, 2024
Primary Completion Date
December 9, 2027
Study Completion Date
December 9, 2027
Conditions
Oropharyngeal NeoplasmsRobotic Surgery and/or RadiotherapyLymphoscintigraphy
Interventions
RADIATION
Arm 1- Ipsilateral
Given by I-RT
Trial Locations (1)
77030
RECRUITING
MD Anderson Cancer Center, Houston
All Listed Sponsors
lead
M.D. Anderson Cancer Center
OTHER
NCT06167291 - Phase II Randomized-registry Embedded Study of Lymphoscintigraphy for Oropharyngeal Neoplasms to Enable Risk-adapted Nodal Guidance for Robotic Surgery and/or Radiotherapy (LONE-RANGR2) | Biotech Hunter | Biotech Hunter